// App-Quantinova.ai

TCT-573 : Randomized comparison of Biolimus-eluting (Nobori) and Everolimus-eluting (Xience/Promus) stents in patients with multivessel coronary artery disease: 12-month follow-up data from COMPARE II study

Researchers

Presenter

  • Peter Smits

Principal Investigators

  • AJ van Boven

  • Mariano Valdes

  • Antonio Serra

  • Jean-Jacques Goy

  • V Voudris

  • Ramiro Trillo

  • JM Vazquez

  • Peter den Heijer

  • Ton Slagboom

  • AG Vuillomenet

Medical Centers

  • Complejo Hospitalario Universitario Juan Canalejo, La Coruna, Spain

  • Hospital Clinico de Santiago de Compostela, Santiago De Compostela, Spain

  • Amphia Hospital Breda, Breda, NB

  • Onze Lieve Vrouwe Gasthuis, Amsterdam, Noord-Holland, Netherlands

  • Hospital Clinico Universitario Virgen de la Arrixaca, Murcia, Spain

  • Hospital de Sant Pau y Santa Creu, Barcelona, Spain

  • Medical Center Leeuwarden, Leeuwarden, Netherlands

  • Kantonsspital Aarau, Zuerich, Switzerland

  • Hospital and University Fribourg, Switzerland, Fribourg, Switzerland

  • Onassis Cardiac Surgery Center, Athens, Greece.

Locations

  • Spain

  • Switzerland

  • Greece

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • Multi-vessel disease

  • Myocardial infarction

  • Diabetes

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • Everolimus

  • Crofelemer

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved